TEM Stock Analysis: Tempus AI, Common Stock | NASDAQ

Diagnostics, Genomics, AI Analytics, Clinical Trials

Total Rating 14

Safety 28

Buy Signal -0.09

Health Information Services
Industry Rotation: -10.0

Market Cap: 9.40B
Avg Turnover: 212M

Risk 3d forecast

Volatility106%

VaR 5^th Pctl17.1%

VaR vs Median-1.52%

Reward TTM

Sharpe Ratio0.03

Rel. Str. IBD40.3

Rel. Str. Peer Group1.8

Character TTM

Beta3.382

Beta Downside3.698

Hurst Exponent0.539

Drawdowns 3y

Max DD59.76%

CAGR/Max DD0.36

CAGR/Mean DD0.64

EPS (Earnings per Share)

Last SUE: 0.15
Qual. Beats: 0

Revenue

Rev. CAGR: 53.28%
Rev. Trend: 98.8%

Last SUE: 0.52
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical

Altman Z'' In Financial Distress Zone

Overextended 3d

Choppy

Tailwinds

Confidence

Ep Pivot

Seasonality 2.1 years of data

Jan -2.4% -

Feb -14.3% -

Mar -18.2% -

Apr +18.2% -

May -5.2% -

Jun +13.5% 35

Jul -17.1% 39

Aug +31.1% -

Sep -0.2% -

Oct +4.1% -

Nov -18.6% -

Dec -28.9% -

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: TEM Tempus AI, Common Stock

Tempus AI, Inc. (NASDAQ: TEM) is a Chicago-based healthcare technology company that applies AI and data analytics to precision medicine. Founded in 2015 and rebranded from Tempus Labs in January 2023, the company went public in June 2024. It operates within the Life Sciences Tools & Services sub-industry, an area focused on providing technologies and analytical services to pharmaceutical, biotechnology, and healthcare organizations.

The company offers an integrated platform built around the Tempus system, which connects clinicians with laboratory diagnostics, analytics, and a multimodal data repository. Its product suite includes Hub, a clinical application for ordering and managing NGS tests; Lens, a software tool for life sciences research; and a broad range of diagnostic services covering next-generation sequencing, PCR profiling, and anatomic and molecular pathology. Core clinical assays (xT and xR) provide large-panel DNA, RNA, and incidental germline analysis, while the nP assay addresses pharmacogenomic testing for psychiatric conditions such as depression and anxiety.

Tempus AI also monetizes its data assets through Insights, which licenses de-identified clinical, molecular, and imaging datasets, and supports clinical research through its Organoids platform, AI tools branded as Next and Algos, and a Trials service for patient-trial matching. The company maintains strategic collaborations with major pharmaceutical partners, including AstraZeneca, GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, and partners with Blood Cancer United on a pediatric acute myeloid leukemia registry.

Headlines to Watch Out For

Data licensing revenue surges on AstraZeneca and GSK partnerships
Diagnostics segment growth accelerates with NGS test volume
Gross margin expansion drives path to profitability

Piotroski VR-10 (Strict) 2.5

Net Income: -254.4m TTM > 0 and > 6% of Revenue
FCF/TA: -0.12 > 0.02 and ΔFCF/TA -7.05 > 1.0
NWC/Revenue: 62.80% < 20% (prev 23.74%; Δ 39.06% < -1%)
CFO/TA -0.10 > 3% & CFO -237.4m > Net Income -254.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.30 > 1.5 & < 3
Outstanding Shares: last quarter (182.4m) vs 12m ago 5.20% < -2%
Gross Margin: 63.98% > 18% (prev 60.73%; Δ 3.25% > 0.5%)
Asset Turnover: 71.76% > 50% (prev 58.57%; Δ 13.19% > 0%)
Interest Coverage Ratio: -3.56 > 6 (EBIT TTM -197.0m / Interest Expense TTM 55.3m)

Altman Z'' -1.39

A: 0.38 (Total Current Assets 1.29b - Total Current Liabilities 391.5m) / Total Assets 2.37b
B: -1.06 (Retained Earnings -2.52b / Total Assets 2.37b)
C: -0.10 (EBIT TTM -197.0m / Avg Total Assets 2.00b)
D: 0.23 (Book Value of Equity 444.9m / Total Liabilities 1.92b)
Altman-Z'' = -1.39 = CCC

Beneish M -2.91

DSRI: 0.94 (Receivables 378.4m/268.8m, Revenue 1.43b/952.0m)
GMI: 0.95 (GM 60.73% / 63.98%)
AQI: 0.75 (AQ_t 0.39 / AQ_t-1 0.52)
SGI: 1.50 (Revenue 1.43b / 952.0m)
TATA: -0.01 (NI -254.4m - CFO -237.4m) / TA 2.37b)
Beneish M = -2.91 (Cap -4..+1) = A

What is the price of TEM shares?

As of August 20, 2026, the stock is trading at USD 61.25 with a total of 21,786,052 shares traded. Over the past week, the price has changed by +12.16%, over one month by +26.52%, over three months by +34.53% and over the past year by -16.19%.

Current recommended Stop Loss: 57.20 (which is 6.6% or 1.3 ATR below the current price).

Is TEM a buy, sell or hold?

Tempus AI, Common Stock has received a consensus analysts rating of 3.83. Therefore, it is recommended to buy TEM.

StrongBuy: 4
Buy: 2
Hold: 6
Sell: 0
StrongSell: 0

What are the forecasts/targets for the TEM price?

Analysts Target Price	62.6	2.3%

Tempus AI, Common Stock (TEM) - Fundamental Data Overview as of 17 August 2026

Market Cap USD = 9.40b (9.40b USD * 1.0 USD.USD)
P/S = 6.5646
P/B = 21.1282
Revenue TTM = 1.43b USD
EBIT TTM = -197.0m USD
EBITDA TTM = -90.9m USD
Long Term Debt = 1.36b USD (from longTermDebt, last quarter)
Short Term Debt = 12.2m USD (from shortTermDebt, last quarter)
Debt = 1.53b USD (from shortLongTermDebtTotal, last quarter) + Leases 83.5m
Net Debt = 711.6m USD (calculated: Debt 1.53b - CCE 816.0m)
Enterprise Value = 10.1b USD (9.40b + Debt 1.53b - CCE 816.0m)
Interest Coverage Ratio = -3.56 (Ebit TTM -197.0m / Interest Expense TTM 55.3m)
EV/FCF = -37.05x (Enterprise Value 10.1b / FCF TTM -273.0m)
FCF Yield = -2.70% (FCF TTM -273.0m / Enterprise Value 10.1b)
FCF Margin = -19.06% (FCF TTM -273.0m / Revenue TTM 1.43b)
Net Margin = -17.77% (Net Income TTM -254.4m / Revenue TTM 1.43b)
Gross Margin = 63.98% ((Revenue TTM 1.43b - Cost of Revenue TTM 515.8m) / Revenue TTM)
Gross Margin QoQ = 64.45% (prev 63.78%)
Tobins Q-Ratio = 4.27 (Enterprise Value 10.1b / Total Assets 2.37b)
Interest Expense / Debt = 3.62% (Interest Expense 55.3m / Debt 1.53b)
Taxrate = 5.19% (309k / 5.95m)
NOPAT = -186.8m (EBIT -197.0m * (1 - 5.19%)) [loss with tax shield]
Current Ratio = 3.30 (Total Current Assets 1.29b / Total Current Liabilities 391.5m)
Debt / Equity = 3.43 (Debt 1.53b / totalStockholderEquity, last quarter 444.9m)
Debt / EBITDA = -7.83 (negative EBITDA) (Net Debt 711.6m / EBITDA -90.9m)
Debt / FCF = -2.61 (negative FCF - burning cash) (Net Debt 711.6m / FCF TTM -273.0m)
Total Stockholder Equity = 465.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.75% (Net Income -254.4m / Total Assets 2.37b)
RoE = -54.70% (Net Income TTM -254.4m / Total Stockholder Equity 465.1m)
RoCE = -10.79% (EBIT -197.0m / Capital Employed (Equity 465.1m + L.T.Debt 1.36b))
RoIC = -9.75% (negative operating profit) (NOPAT -186.8m / Invested Capital 1.92b)
WACC = 15.86% (E(9.40b)/V(10.9b) * Re(17.88%) + D(1.53b)/V(10.9b) * Rd(3.62%) * (1-Tc(0.05)))
Discount Rate = 17.88% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 82.23 | Cagr: 3.21%
[DCF] Fair Price = unknown (Cash Flow -273.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.15 | # QB: 0
Revenue Correlation: 98.78 | Revenue CAGR: 53.28% | SUE: 0.52 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.07 | Chg30d=+17.67% | Revisions=+36% | Analysts=11
EPS current Year (2026-12-31): EPS=-0.26 | Chg30d=+32.59% | Revisions=+62% | GrowthEPS=+57.9% | GrowthRev=+25.6%
EPS next Year (2027-12-31): EPS=-0.02 | Chg30d=+85.41% | Revisions=+58% | GrowthEPS=+94.1% | GrowthRev=+23.4%
[Analyst] Revisions Ratio: +63% (up=23, down=4)